Sorafenib is the standard of care in advanced hepatocellular carcinoma. This study was aimed to identify clinical parameters that may predict survival in these patients.
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma / Di Costanzo, Giovan Giuseppe; de Stefano, Giorgio; Tortora, Raffaella; Farella, Nunzia; Addario, Luigi; Lampasi, Filippo; Lanza, Alfonso Galeota; Cordone, Gabriella; Imparato, Michele; Caporaso, Nicola. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 11:6(2015), pp. 943-51-951. [10.2217/fon.14.291]
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma
TORTORA, RAFFAELLA;CORDONE, GABRIELLA;CAPORASO, NICOLA
2015
Abstract
Sorafenib is the standard of care in advanced hepatocellular carcinoma. This study was aimed to identify clinical parameters that may predict survival in these patients.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.